AbbVie Presents Data for ABBV-466, a Novel Dual-Targeting Therapy Demonstrating Higher Endoscopic Remission Rates Than Either Anti-IL-23 or Anti-α4β7 Monotherapy in Moderate to Severe Crohn's Disease

Week 24 remission rates were 40.5% with the combination, compared with 22.4% and 20.0% with the individual therapies.

Rhea-AI Summary

AbbVie (NYSE: ABBV) reported higher endoscopic remission rates with investigational ABBV-466 than either monotherapy in a Phase 2a Crohn's disease study. The ongoing, open-label TARGET-CD trial randomized 300 patients to ABBV-466, risankizumab or trosunilimab for 24 weeks. ABBV-466 combines the two therapies.

At Week 12, the primary endpoint, remission measured by bowel examination reached 30.2% with ABBV-466, versus 21.3% with risankizumab and 18.0% with trosunilimab. At Week 24, rates were 40.5%, 22.4% and 20.0%, respectively. Gene expression analyses showed intestinal tissue repair and barrier restoration at Week 12, followed by tissue remodeling and metabolic changes at Week 24. Serious adverse events occurred in 10.4% of ABBV-466 patients, versus 9.6% and 9.0% with the respective monotherapies. Results will be presented at the 2026 United European Gastroenterology Week Congress.

4 points · 1 major

PositiveiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 2 points

How the balance works

Positive

• Major pointABBV-466 Week 12 remission reached 30.2%, versus 21.3% with risankizumab and 18.0% with trosunilimab.
• Moderate pointABBV-466 Week 24 remission reached 40.5%, versus 22.4% with risankizumab and 20.0% with trosunilimab.
• Minor pointGene expression analyses showed tissue repair and barrier restoration at Week 12 with ABBV-466.
• Minor pointABBV-466 showed Week 24 tissue remodeling and metabolic changes generally not observed with either monotherapy.

Negative

• Minor pointSerious adverse events occurred in 10.4% with ABBV-466, versus 9.6% with risankizumab and 9.0% with trosunilimab.
• Minor pointABBV-466's most common adverse events, occurring in ≥5%, were Crohn's disease and nausea.

Key Figures

Week 12 endoscopic remission: 30.2% ABBV-466; 21.3% anti-IL-23 p19; 18.0% anti-α4β7 Week 24 endoscopic remission: 40.5% ABBV-466; 22.4% risankizumab; 20.0% trosunilimab Study enrollment: 300 patients +1 more

Week 12 endoscopic remission

30.2% ABBV-466; 21.3% anti-IL-23 p19; 18.0% anti-α4β7

Phase 2a TARGET-CD primary endpoint

Week 24 endoscopic remission

40.5% ABBV-466; 22.4% risankizumab; 20.0% trosunilimab

Phase 2a TARGET-CD

Study enrollment

300 patients

TARGET-CD study

Serious adverse events

10.4% ABBV-466; 9.6% risankizumab; 9.0% trosunilimab

Through Week 24

Historical Context

1 past event · Latest: Oct 13

1 event

1. Oct 13

   Phase 3 Crohn's data

   24h Move

   -2.4%

   Phase 3 SKYRIZI Crohn's data reported Week 12 and Week 24 endoscopic remission versus placebo.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

endoscopic remission, primary endpoint, open-label, gene expression analysis, +1 more

5 terms

endoscopic remission medical

"achieved higher rates of endoscopic remission at Week 12"

Endoscopic remission is when a doctor looks inside the digestive tract with a camera and finds no visible signs of inflammation or ulcers. For investors, it matters because this objective, image-based outcome is often used by regulators and doctors to judge whether a treatment truly works, much like a clear windshield shows the road is unobstructed — it can drive regulatory approval, prescribing decisions, and market value for a therapy.

primary endpoint medical

"at Week 12, the primary endpoint"

The primary endpoint is the single main result a clinical study is designed to measure to decide if a treatment works, like the finish line in a race that tells you who won. Investors care because meeting or missing this goal drives regulatory decisions, future sales expectations and stock value — it turns trial data into a clear yes-or-no signal about a drug’s commercial prospects.

open-label medical

"an ongoing open-label, treat-through, Phase 2a platform study"

Open-label describes a situation where everyone involved in a study or process knows the full details, such as who is receiving a treatment or intervention. For investors, understanding whether a project or product is open-label helps gauge the level of transparency and potential biases, influencing trust and decision-making. It’s like knowing whether a test or experiment is conducted openly or behind closed doors.

gene expression analysis technical

"Gene expression analysis showed ABBV-466 treated Crohn's disease patients"

Measurement and comparison of which genes are being transcribed into RNA in a biological sample and how much RNA each gene produces, used to determine which genes are active or suppressed under particular conditions. Common laboratory methods include quantitative PCR, microarrays and RNA sequencing; the results represent a snapshot of RNA levels (not direct protein amounts or functional activity) and can be affected by sample type, timing and handling.

jak inhibitor medical

"12% had failed a JAK inhibitor"

A JAK inhibitor is a type of medicine that blocks Janus kinase enzymes, which help cells send signals that drive inflammation and immune activity. By turning down that cellular “volume knob,” these drugs can reduce symptoms in autoimmune diseases and certain blood disorders. Investors watch JAK inhibitors because their effectiveness, safety profile, approval status, and patent position directly affect drug sales, market competition, and regulatory risk for companies developing or selling them.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• In a Phase 2a study, ABBV-466 achieved higher endoscopic remission rates in patients with Crohn's disease than either anti-IL-23 p19 or anti-α4β7 monotherapy at Week 12, the primary endpoint. The treatment difference between ABBV-466 and the monotherapy groups further increased at Week 24¹
• Gene expression analysis showed that ABBV-466 treated Crohn's disease patients experienced intestinal tissue repair and barrier restoration by Week 12, with tissue remodeling and metabolic changes reported at Week 24¹
• The results will be presented as a late-breaker at the 2026 Annual United European Gastroenterology Week Congress

NORTH CHICAGO, Ill., Oct. 19, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that its investigational ABBV-466, a novel dual-targeting therapy against IL-23 p19 and integrin α4β7, demonstrated higher rates of endoscopic remission^a at Week 12 than either monotherapy in patients with Crohn's disease (CD). The difference in endoscopic remission^a rates between ABBV-466 and monotherapy groups further increased at Week 24. The findings are from the TARGET-CD study, an ongoing open-label, treat-through, Phase 2a platform study in patients with moderate to severe CD.^1,2 The findings will be presented as a late-breaking abstract at the ongoing 2026 Annual United European Gastroenterology Week (UEGW) Congress in Barcelona, October 17–20.

"ABBV-466 reflects how we are building the next generation of our inflammatory bowel disease (IBD) portfolio, leveraging insights from our own research to address disease pathways that may remain active even when a central inflammatory pathway is inhibited," said Kori Wallace, M.D., vice president, global head of immunology clinical development, AbbVie. "Our research pointed to evidence of α4β7-driven inflammation despite risankizumab's IL-23 p19 inhibition, leading us to augment risankizumab with a novel α4β7 inhibitor, trosunilimab. The TARGET-CD results reinforce our strategy of advancing therapies designed around the complex biology of Crohn's disease."

The TARGET-CD study included 300 patients (94, 100, and 106 patients in the anti-IL-23 p19 (risankizumab), anti-α4β7 (trosunilimab), and ABBV-466 treatment groups, respectively) with moderately to severely active Crohn's disease across the spectrum of disease severity and prior treatment experience. While 25% of patients were biologic-naïve, 75% had failed at least one advanced therapy, including 9.3% who had failed prior IL-23 therapy and 12% who had failed a JAK inhibitor; 25% had failed three or more advanced therapies. This patient population reflects the real-world complexity of Crohn's disease, where heterogeneous disease biology can contribute to differences in treatment response across patients.¹

At Week 12, 30.2% of patients treated with ABBV-466 achieved the primary endpoint of endoscopic remission^a, compared to 21.3% and 18.0% of patients receiving anti-IL-23 p19 monotherapy and anti-α4β7 monotherapy, respectively. An improvement with ABBV-466 was also reported at Week 24, with 40.5% of ABBV-466 treated patients achieving endoscopic remission^a, compared to 22.4% and 20.0% of patients on risankizumab and trosunilimab monotherapy, respectively.¹

Based on gene expression analyses, ABBV-466 showed colonic epithelial repair and barrier restoration at Week 12, followed by tissue remodeling and metabolic changes at Week 24 that were generally not observed with either monotherapy.¹ 

"Many patients with Crohn's disease move from one advanced therapy to the next and still have active inflammation in the bowel, even when their symptoms improve," said Remo Panaccione, M.D., Professor of Medicine and Director of the Inflammatory Bowel Disease Unit, Division of Gastroenterology and Hepatology, University of Calgary. "Endoscopic remission is a goal we aim for, because ongoing inflammation can drive disease progression over time. What stands out in the TARGET-CD Phase 2a study is that a dual-targeting approach reached that goal more often than either therapy alone in a heavily pretreated population."

Rates of serious adverse events (SAEs) for ABBV-466 were 10.4% and comparable to risankizumab monotherapy (9.6%) and trosunilimab monotherapy (9.0%). In the ABBV-466 and trosunilimab monotherapy arms, the most common adverse events (≥5%) were Crohn's disease and nausea. In the risankizumab monotherapy arm, the most common adverse events (≥5%) were Crohn's disease and arthralgia.¹

Additional information about the program can be found on clinicaltrials.gov under the identifier NCT06548542. 

UEGW Presentation Details: 

Abstract Title	Date/Time	Session Location
ABBV-466, A Novel Dual-Targeting Therapy, Leads to Endoscopic Remission in Moderate-to-Severe Crohn's Disease: Primary Results and Molecular Profiling From the Phase 2a TARGET-CD Study	Monday, October 19, 2026; 10:10 – 10:20 a.m. CEST	Room UEG Forum

aDefined as Simple Endoscopic Score for CD (SES-CD) ≤4 and no sub score greater than 1 in any individual variable

About TARGET-CD
TARGET-CD (NCT06548542) is an ongoing open-label, treat-through Phase 2a platform study in patients with moderate-to-severe Crohn's disease. Patients were randomized 1:1:1 to receive 24 weeks of ABBV-466, risankizumab or trosunilimab. The primary endpoint was endoscopic remission^a at Week 12. Additional prespecified endpoints were assessed at Weeks 12 and 24, with safety assessed through Week 24. SES-CD is an assessment tool used during colonoscopy to measure the severity of inflammation and damage in patients with Crohn's disease.

About ABBV-466
ABBV-466 is an investigational dual-targeting therapy combining risankizumab, an IL-23 inhibitor, with trosunilimab, an α4β7 inhibitor, to address complementary drivers of inflammation in Crohn's disease. The approach is designed to inhibit inflammatory signaling while limiting immune-cell trafficking to the gut, with the goal of achieving deeper disease control than either pathway alone.

ABBV-466 is investigational, and its safety and efficacy have not been established by regulatory authorities.

EU Indications and Important Safety Information about SKYRIZI^® (risankizumab)³

Indications
Skyrizi (risankizumab) is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.

Skyrizi is indicated for the treatment of moderate to severe plaque psoriasis in children and adolescents from the age of 6 years who are candidates for systemic therapy.

Skyrizi, alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (DMARDs).

Skyrizi is indicated for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.

Skyrizi is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.

Important Safety Information 
Risankizumab is contraindicated in patients hypersensitive to the active substance or to any of the excipients, and in patients with clinically important active infections (e.g., active tuberculosis).

Risankizumab may increase the risk of infection. In patients with a chronic infection, a history of recurrent infection, or known risk factors for infection, risankizumab should be used with caution. Treatment with risankizumab should not be initiated in patients with any clinically important active infection until the infection resolves or is adequately treated.

Patients treated with risankizumab should be instructed to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops such an infection or is not responding to standard therapy for the infection, the patient should be closely monitored and risankizumab should not be administered until the infection resolves.

Prior to initiating treatment with risankizumab, patients should be evaluated for tuberculosis (TB) infection. Patients receiving risankizumab should be monitored for signs and symptoms of active TB. Anti-TB therapy should be considered prior to initiating risankizumab in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed.

Prior to initiating therapy with risankizumab, completion of all appropriate immunizations should be considered according to current immunization guidelines. If a patient has received live vaccination (viral or bacterial), it is recommended to wait at least 4 weeks prior to starting treatment with risankizumab. Patients treated with risankizumab should not receive live vaccines during treatment and for at least 21 weeks after treatment.

Serious hypersensitivity reactions, including anaphylaxis, have been reported with use of risankizumab. If a serious hypersensitivity reaction occurs, administration of risankizumab should be discontinued immediately and appropriate therapy initiated.

The most frequently reported adverse reactions were upper respiratory infections (13% in psoriasis, 15.6% in Crohn's disease and 26.2% in ulcerative colitis).

Commonly (≥ 1/100 to < 1/10) reported adverse reactions included tinea infections, headache, pruritus, rash, eczema, fatigue, and injection site reactions.

This is not a complete summary of all safety information.

See Skyrizi full Summary of Product Characteristics (SmPC) at http://www.ema.europa.eu

Globally, prescribing information varies; refer to the individual country product label for complete information.

About AbbVie in Immunology
AbbVie is relentless in our pursuit to redefine the standard of care for patients living with immune-mediated conditions, with the goal of helping them live a life free from the limitations of their disease. For nearly 30 years, AbbVie has led and helped shape the field of immunology through groundbreaking science and trusted medicines. Building on deep expertise across gastroenterology, rheumatology, dermatology and other areas of high unmet need, we continue to invest in a broad and differentiated pipeline – spanning innovative modalities, novel mechanisms of action and next-generation approaches designed to conquer the complex biology underlying immune-mediated disease. 

Today, more than 1 million patients worldwide are treated with AbbVie's immunology medicines, approved in more than 175 countries across 20+ immune-mediated diseases that impact adult and pediatric populations. As we work to strengthen our legacy and drive the next wave of innovation, we remain focused on delivering meaningful progress for patients and expanding access to our medicines. For more information, please visit www.abbvie.com/immunology. 

About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube.

Forward-Looking Statements 
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2025 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law. 

References:

1. AbbVie. Data on file. ABVRRTI84181
2. Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease (Target CD). ClinicalTrials.gov. Available at: https://clinicaltrials.gov/study/NCT06548542. Accessed October 10, 2026.
3. SKYRIZI. Summary of product characteristics. AbbVie; 2026. 

Media: Olipriya Das olipriya.das@abbvie.com	Investors: Liz Shea liz.shea@abbvie.com
Jit Bhowmick jit.bhowmick@abbvie.com

View original content:https://www.prnewswire.com/news-releases/abbvie-presents-data-for-abbv-466-a-novel-dual-targeting-therapy-demonstrating-higher-endoscopic-remission-rates-than-either-anti-il-23-or-anti-47-monotherapy-in-moderate-to-severe-crohns-disease-302911816.html

SOURCE AbbVie

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did AbbVie's ABBV-466 Crohn's disease trial show?

ABBV-466 achieved 30.2% endoscopic remission at Week 12, the primary endpoint, compared with 21.3% for risankizumab and 18.0% for trosunilimab. At Week 24, remission rates were 40.5%, 22.4% and 20.0%, respectively.

How was remission defined in AbbVie's TARGET-CD study?

Endoscopic remission required a Simple Endoscopic Score for Crohn's disease of ≤4, with no individual variable subscore greater than 1. This scoring tool uses colonoscopy to assess inflammation and damage in patients with Crohn's disease.

What prior treatments had patients in AbbVie's ABBV-466 trial received?

75% of patients had failed at least one advanced therapy, while 25% were biologic-naïve. The study population included 9.3% who had failed prior IL-23 therapy, 12% who had failed a JAK inhibitor and 25% who had failed three or more advanced therapies.